Switch theme
Sign up to access all valuation multiples
Solesence Inc is a scientifically driven health care solutions company across beauty and life science categories, protecting skin from environmental aggressors and enhancing the aesthetic appeal of healthy products. The group is engaged in the beauty category that develops and manufactures clean, inclusive, mineral-based skincare and makeup products at the forefront of skin health. Its brands are Stress Defense, Kleair, and Bloom.
1989
98
Last FY Revenue $52.3M
Last FY EBITDA $6.1M
$282M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Solesence achieved revenue of $52.3M and an EBITDA of $6.1M.
Solesence expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Solesence valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $52.3M | XXX | XXX | XXX |
| Gross Profit | XXX | $16.2M | XXX | XXX | XXX |
| Gross Margin | XXX | 31% | XXX | XXX | XXX |
| EBITDA | XXX | $6.1M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 12% | XXX | XXX | XXX |
| EBIT | XXX | $5.1M | XXX | XXX | XXX |
| EBIT Margin | XXX | 10% | XXX | XXX | XXX |
| Net Profit | XXX | $4.2M | XXX | XXX | XXX |
| Net Margin | XXX | 8% | XXX | XXX | XXX |
| Net Debt | XXX | $3.6M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 31, 2025, Solesence's stock price is $4.
Solesence has current market cap of $261M, and EV of $282M.
See Solesence trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $282M | $261M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 31, 2025, Solesence has market cap of $261M and EV of $282M.
Solesence's trades at 5.4x EV/Revenue multiple, and 46.6x EV/EBITDA.
Equity research analysts estimate Solesence's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Solesence's P/E ratio is not available.
See valuation multiples for Solesence and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $261M | XXX | $261M | XXX | XXX | XXX |
| EV (current) | $282M | XXX | $282M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 5.4x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 46.6x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 55.0x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 61.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -109.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSolesence's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.1M for the same period.
Solesence's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Solesence's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Solesence and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 12% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 7% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 21% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Acme United | XXX | XXX | XXX | XXX | XXX | XXX |
| EZZ Life Science | XXX | XXX | XXX | XXX | XXX | XXX |
| Lavipharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Sarantis Group | XXX | XXX | XXX | XXX | XXX | XXX |
| PharmaSGP | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Solesence acquired XXX companies to date.
Last acquisition by Solesence was XXXXXXXX, XXXXX XXXXX XXXXXX . Solesence acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Solesence founded? | Solesence was founded in 1989. |
| Where is Solesence headquartered? | Solesence is headquartered in United States of America. |
| How many employees does Solesence have? | As of today, Solesence has 98 employees. |
| Who is the CEO of Solesence? | Solesence's CEO is Mr. Jess A. Jankowski. |
| Is Solesence publicy listed? | Yes, Solesence is a public company listed on NAS. |
| What is the stock symbol of Solesence? | Solesence trades under SLSN ticker. |
| When did Solesence go public? | Solesence went public in 1997. |
| Who are competitors of Solesence? | Similar companies to Solesence include e.g. Acme United, EZZ Life Science, Lavipharm, Sarantis Group. |
| What is the current market cap of Solesence? | Solesence's current market cap is $261M |
| Is Solesence profitable? | Yes, Solesence is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
